Roll No.

Total No. of Pages : 02

Total No. of Questions : 07

M.Sc. (Clinical Research) (Sem.-3) PHARMACOECONOMICS & HEALTH TECHNOLOGY ASSESSMENT Subject Code : UC-MSCR313-19

M.Code: 79937

Date of Examination : 23-12-22

Time : 2 Hrs.

Max. Marks : 35

INSTRUCTIONS TO CANDIDATES :

- 1. SECTION-A is COMPULSORY consisting of FIVE questions carrying ONE marks each.
- 2. SECTION-B contains THREE questions carrying FIVE marks each and students have to attempt any TWO questions.
- 3. SECTION-C contains THREE questions carrying TEN marks each and students have to attempt any TWO questions.

SECTION-A

- 1. Answer briefly:
 - a. Why is significance of Health Economics?
 - b. What are the four basic types of pharmacoeconomic analysis?
 - c. Intervention A has utility score of 0.7 and length of life 5 years, intervention B has utility score of 0.5 and length of life 10 years. Which intervention is better in terms of QALYs?
 - d. What is health technology assessment?
 - e. What is bottom-up costing method in health technology assessment?

SECTION-B

- 2. Compare and contrast different types of pharmacoeconomic analyses.
- 3. Explain incremental cost-effectiveness ratio.
- 4. What is the scope of health technology assessment?

SECTION-C

- 5. Two interventions, Breathe Again and inhaled corticosteroids were compared. Total cost of treatment with Breathe Again was \$537 and it provided 90SFD. The cost of treatment with inhaled corticosteroids was \$320 and it provided 45 SFD. A day without asthma symptoms is worth \$5. Perform incremental net benefit analysis and comment if Breathe Again is cost effective.
- 6. What do you understand by "perspective in pharmacoeconomics analyses"? What are the different types of perspective and how do they differ from each other?
- 7. How do you conduct a health technology assessment? Discuss in detail.

NOTE : Disclosure of Identity by writing Mobile No. or Marking of passing request on any paper of Answer Sheet will lead to UMC against the Student.